Edmund K Waller MD

Hematologic Oncology

Professor of Hematology & Oncology, Emory University

Summary

Dr. Edmund Waller is a hematologist oncologist in Atlanta, GA and is affiliated with multiple hospitals in the area, including Emory University Hospital, Emory University Hospital Midtown, and Grady Memorial Hospital. He received his medical degree from Weill Cornell Medical College of Cornell University and his PhD from Rockefeller University. Following clinical training in Medicine and Medical Oncology at Stanford University and working at Becton Dickinson in San Jose, he has been in practice at Emory for 27 years. He manages an active R01 and P01-funded basic science and translational research laboratory. He has founded two biotech start-ups, Cambium Medical Technologies, a clinical stage company developing Elate Ocular to treat ocular GvHD, and Cambium Oncology, a pre-clinical company developing first-in-class antagonists of a novel immune check-point pathway mediated by signaling through the receptor for vasoactive intestinal polypeptide (VIP). He has clinical expertise in hematologic oncology, cancer immunotherapy, CART, and hematopoietic stem cell transplantation for lymphoma, myeloid malignancies, sickle cell anemia and germ cell cancer. .

Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1988 - 1993
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1985 - 1988
Weill Cornell MedicineClass of 1985
Rockefeller UniversityPhD, Chemical Biology, 1978 - 1984
Harvard UniversityAB, Biology, Magna Cum Laude, 1974 - 1978

Fellow American Association for the Advancement of Science American Association for the Advancement of Science, 2025
Fellow National Academy of Inventors National Academy of Inventors, 2025
America's Top Doctors for Cancer Castle Connolly, 2011-2022

PubMed

Journal Articles

The Potential of CAR T Cell Therapy in Pancreatic Cancer
Mehmet Akce, Mohammad Y Zaidi, Edmund K Waller, Frontiers in Neurology
Recipient Single Nucleotide Polymorphisms in Paneth Cell Antimicrobial Peptide Genes and Acute Graft‐Versus‐Host Disease: Analysis of BMT CTN‐0201 and ‐0901 Samples
Armin Rashidi, Edmund K Waller, Bharat Thyagarajan, Claudio Anasetti, Daniel J Weisdorf, Bart L Scott, Bruce R Blazar, British Journal of Haematology
Indoles Derived from Intestinal Microbiota Act via Type I Interferon Signaling to Limit Graft-Versus-Host-Disease
Edmund K Waller, Zachariah DeFilipp, Muna Qayed, Akshay Sharma, Blood

Abstracts/Posters

Outcomes of Elderly Patients Undergoing Allogeneic Transplantation for Acute Myeloid Leukemia with Fludarabine/Melphalan or Fludarabine/TBI Conditioning Regimen
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
IMPACT-TB*: A Phase II Trial Assessing the Capacity of Low Dose Imatinib to Induce Myelopoiesis and Enhance Host Anti-Microbial Immunity Against Tuberculosis. *Imatini...
Edmund K. Waller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Research Roundup: Recent Grants and Publications for Emory Faculty and StaffMarch 10th, 2022
Research Roundup: Recent Grants and Publications for Emory Faculty and StaffSeptember 21st, 2021
NIAID Supports Clinical Testing of Anti-Cancer Drug for TBAugust 15th, 2017

BMT Core: Southeast Bone Marrow Transplant ConsortiumEMORY UNIVERSITY2024–2031
BMT Core: Southeast Bone Marrow Transplant ConsortiumEMORY UNIVERSITY2024–2031
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancerEMORY UNIVERSITY2024–2029
Leveraging CD26high Meso-CAR T cells in patients with advanced pancreatic cancerEMORY UNIVERSITY2024–2029
Development of a Novel Immunotherapeutic for Acute Myeloid LeukemiaCAMBIUM ONCOLOGY LLC2024–2027